• İstanbul 17 °C
  • Ankara 10 °C

UK: Another COVID-19 vaccine enters final stage trials

UK: Another COVID-19 vaccine enters final stage trials
Novavax to prioritize elderly and ethnic minorities in Phase 3 trials of its coronavirus vaccine

By Karim El-Bar

LONDON (AA) - Another coronavirus vaccine has entered the final Phase 3 trial stage in the UK, a US vaccine development company said on Friday.

In a press release, Novavax said it will sign up 10,000 volunteers between 18 and 84 years of age over the next four to six weeks.

Half of the volunteers will be given a placebo, while the other half will be given two shots of its vaccine.

Up to 400 people will take the vaccine in combination with a seasonal flu vaccine to see how effective a combination both together make.

Novavax said that pre-clinical trials showed its vaccine candidate was “generally well-tolerated” and produced “robust antibody responses.”

The company also said that at least a quarter of volunteers will be over 65 years old, as they want to ensure the trials prioritize those vulnerable to COVID-19. This includes a focus on ethnic minorities too.

Last August, the UK government struck a deal with Novavax, with the government giving the US company support and infrastructure in exchange for Novavax manufacturing the vaccine in the UK and giving Britain 60 million doses if it proves to be safe and effective.

It is the fourth vaccine in the world to enter the final stage of the regulatory process, joining AstraZeneca, Pfizer, and Moderna.

In the UK, it is the second to reach this milestone, following the vaccine being developed by AstraZeneca and Oxford University.

source: News Feed
This news is a total 22 time has been read
UYARI: Küfür, hakaret, rencide edici cümleler veya imalar, inançlara saldırı içeren, imla kuralları ile yazılmamış,
Türkçe karakter kullanılmayan ve büyük harflerle yazılmış yorumlar onaylanmamaktadır.
This news yet comment has been added .
Other News
All Rights Reserved © May 2014 US Muslims | Unauthorized and the resources published.
Haber Scripti: CM Bilişim